What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to formally announce Abbott Laboratories' financial results for the second quarter of 2021. It directs investors to a press release (Exhibit 99.1) for the detailed financial information.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from standard GAAP (Generally Accepted Accounting Principles) calculations. Abbott uses them to provide investors with a clearer view of the company's ongoing operational performance by removing the impact of unusual or unpredictable events such as acquisition-related costs, restructuring, or litigation expenses. Management believes these measures help in assessing the core business performance.

Where can I find the actual Q2 2021 financial results?

The specific financial results for the second quarter of 2021 are detailed in the press release issued by Abbott Laboratories on July 22, 2021, which is filed as Exhibit 99.1 with this 8-K report. Investors should refer to that document for revenue, earnings, and segment performance details.

What is the significance of Exhibit 99.1?

Exhibit 99.1 is the press release announcing Abbott's Q2 2021 results. This is the primary source of detailed financial performance information, including any specific figures and commentary on business segments, for the reported quarter. The 8-K filing itself mainly serves to officially submit this press release to the SEC.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on July 22, 2021, to report its second quarter 2021 financial results. The filing primarily references a press release (Exhibit 99.1) which details the company's operational and financial performance for the period. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, adjusting for items such as acquisition-related expenses, restructuring costs, litigation, and other unusual or unpredictable factors. These non-GAAP measures are presented to offer a clearer view of the ongoing business performance as assessed by management, and are intended to supplement, not replace, GAAP-based reporting. While the 8-K itself is procedural, the accompanying press release is the crucial document for understanding Abbott's quarterly performance. Investors will need to refer to Exhibit 99.1 for specific financial figures, including revenue, earnings, and segment performance. The company's use of non-GAAP measures, while common practice, means investors should carefully review both the GAAP and non-GAAP figures to gain a comprehensive understanding of the company's financial health and operational efficiency.

Key Highlights

1Abbott Laboratories filed an 8-K on July 22, 2021, announcing its Q2 2021 financial results.
2The report references a press release (Exhibit 99.1) containing the detailed Q2 2021 financial results.
3Abbott utilizes non-GAAP financial measures in its earnings announcements, adjusting for specific unusual or unpredictable items.
4Examples of adjustments in non-GAAP measures include acquisition expenses, restructuring costs, litigation, and certain tax items.
5The company states that non-GAAP measures provide greater visibility into ongoing business performance, as assessed by management.
6Investors are advised to consider non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.
7The filing was signed by Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 22, 2021)

Summary

Key Highlights

Frequently Asked Questions